tetano
Editor, Senior Moderator
ERJ Open Res
. 2023 Mar 27;9(2):00605-2022.
doi: 10.1183/23120541.00605-2022. eCollection 2023 Mar.
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study
Phillip D Monk[SUP] 1 [/SUP], Jody L Brookes[SUP] 1 [/SUP], Victoria J Tear[SUP] 1 [/SUP], Toby N Batten[SUP] 2 [/SUP], Marcin Mankowski[SUP] 3 [/SUP], Tatjana Adzic-Vukicevic[SUP] 4 [/SUP], Michael G Crooks[SUP] 5 [/SUP], Davinder P S Dosanjh[SUP] 6 [/SUP], Monica Kraft[SUP] 7 8 [/SUP], Christopher E Brightling[SUP] 9 [/SUP], Felicity J Gabbay[SUP] 3 [/SUP], Stephen T Holgate[SUP] 10 [/SUP], Ratko Djukanovic[SUP] 10 [/SUP], Tom M A Wilkinson[SUP] 10 [/SUP]
Affiliations
Abstract
Background: Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus 2. SNG001 is a recombinant IFN-β1a formulation delivered to the lungs via nebuliser. SPRINTER assessed the efficacy and safety of SNG001 in adults hospitalised due to COVID-19 who required oxygen via nasal prongs or mask.
Methods: Patients were randomised double-blind to SNG001 (n=309) or placebo (n=314) once daily for 14 days plus standard of care (SoC). The primary objective was to evaluate recovery after administration of SNG001 versus placebo, in terms of times to hospital discharge and recovery to no limitation of activity. Key secondary end-points were progression to severe disease or death, progression to intubation or death and death.
Results: Median time to hospital discharge was 7.0 and 8.0 days with SNG001 and placebo, respectively (hazard ratio (HR) 1.06 (95% CI 0.89-1.27); p=0.51); time to recovery was 25.0 days in both groups (HR 1.02 (95% CI 0.81-1.28); p=0.89). There were no significant SNG001-placebo differences for the key secondary end-points, with a 25.7% relative risk reduction in progression to severe disease or death (10.7% and 14.4%, respectively; OR 0.71 (95% CI 0.44-1.15); p=0.161). Serious adverse events were reported by 12.6% and 18.2% patients with SNG001 and placebo, respectively.
Conclusions: Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.
. 2023 Mar 27;9(2):00605-2022.
doi: 10.1183/23120541.00605-2022. eCollection 2023 Mar.
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study
Phillip D Monk[SUP] 1 [/SUP], Jody L Brookes[SUP] 1 [/SUP], Victoria J Tear[SUP] 1 [/SUP], Toby N Batten[SUP] 2 [/SUP], Marcin Mankowski[SUP] 3 [/SUP], Tatjana Adzic-Vukicevic[SUP] 4 [/SUP], Michael G Crooks[SUP] 5 [/SUP], Davinder P S Dosanjh[SUP] 6 [/SUP], Monica Kraft[SUP] 7 8 [/SUP], Christopher E Brightling[SUP] 9 [/SUP], Felicity J Gabbay[SUP] 3 [/SUP], Stephen T Holgate[SUP] 10 [/SUP], Ratko Djukanovic[SUP] 10 [/SUP], Tom M A Wilkinson[SUP] 10 [/SUP]
Affiliations
- PMID: 36994453
- PMCID: PMC9790107
- DOI: 10.1183/23120541.00605-2022
Abstract
Background: Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus 2. SNG001 is a recombinant IFN-β1a formulation delivered to the lungs via nebuliser. SPRINTER assessed the efficacy and safety of SNG001 in adults hospitalised due to COVID-19 who required oxygen via nasal prongs or mask.
Methods: Patients were randomised double-blind to SNG001 (n=309) or placebo (n=314) once daily for 14 days plus standard of care (SoC). The primary objective was to evaluate recovery after administration of SNG001 versus placebo, in terms of times to hospital discharge and recovery to no limitation of activity. Key secondary end-points were progression to severe disease or death, progression to intubation or death and death.
Results: Median time to hospital discharge was 7.0 and 8.0 days with SNG001 and placebo, respectively (hazard ratio (HR) 1.06 (95% CI 0.89-1.27); p=0.51); time to recovery was 25.0 days in both groups (HR 1.02 (95% CI 0.81-1.28); p=0.89). There were no significant SNG001-placebo differences for the key secondary end-points, with a 25.7% relative risk reduction in progression to severe disease or death (10.7% and 14.4%, respectively; OR 0.71 (95% CI 0.44-1.15); p=0.161). Serious adverse events were reported by 12.6% and 18.2% patients with SNG001 and placebo, respectively.
Conclusions: Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.